FDA Updates Draft Guidance for Generic Peptide Drug Development

The U.S. Food and Drug Administration (FDA) has issued 17 revised draft product-specific guidances for peptide products. This initiative aims to streamline the assessment of abbreviated new drug applications (ANDAs) for generic peptides. The updates are intended to facilitate the development of generic drugs and enhance patient access to safe and effective medications by clarifying submission requirements, impurity thresholds, and biological activity assessments.